Lv1
20 积分 2026-04-16 加入
Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in Graves’ orbitopathy: a systematic review and meta-analysis
1个月前
已完结
The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy
1个月前
已完结
Teprotumumab versus intravenous methylprednisolone in thyroid eye disease: A systematic review
2个月前
已完结
Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease
2个月前
已完结
Teprotumumab-Associated Hyperglycemia: A Large-Scale Multinational Cohort Study
2个月前
已完结
Teprotumumab-Related Hyperglycemia
2个月前
已完结
Teprotumumab for the Treatment of Active Thyroid Eye Disease
2个月前
已完结
Graves disease: latest understanding of pathogenesis and treatment options
2个月前
已完结
皖公网安备34019202002308
